CrossrefInfokarte
Drug repositioning of regorafenib for renal cell carcinoma identifies DDR2 ‑associated sensitivity in ACHN models
The Korean Journal of Physiology & Pharmacology · 2026-01-01 · 30 (1) · 41-48
DOI: 10.4196/kjpp.25.355 ↗Abstract
Kein Abstract verfügbar.
EUVIMED